I agree that this site is using cookies. You can find further informations here.
X
Ghia, P.
1422  results:
Search for persons X
?
1

ESMO Clinical Practice Guideline interim update on new targ..:

Eichhorst, B. ; Ghia, P. ; Niemann, C.U....
Annals of Oncology.  , 2024
Link: https://doi.org/10.1016/..
 
?
2

FIXED‐DURATION IBRUTINIB + VENETOCLAX IN CHRONIC LYMPHOCYTI..:

Ghia, P. ; Allan, J. N. ; Siddiqi, T....
Hematological Oncology.  41 (2023)  S2 - p. 238-239 , 2023
Link: https://doi.org/10.1002/..
 
?
3

Zanubrutinib safety/tolerability profile and comparison wit..:

Brown, J. R. ; Eichorst, B. ; Ghia, P....
Hematological Oncology.  41 (2023)  S2 - p. 459-461 , 2023
Link: https://doi.org/10.1002/..
 
?
4

Dynamic 3D culture promotes lymphoid tissue maturation and ..:

Barozzi, D. ; Scagnoli, F. ; Mantegazza, F....
Biomedical Science and Engineering.  4 (2023)  1 - p. , 2023
Link: https://doi.org/10.4081/..
 
?
5

Characterization of Mechanisms of Resistance in Previously ..:

Woyach, J. A. ; Jones, D. ; Jurczak, W....
Hematological Oncology.  41 (2023)  S2 - p. 249-250 , 2023
Link: https://doi.org/10.1002/..
 
?
6

EE82 A Cost-Utility Analysis of the MyPal eHealth Applicati..:

Naoum, P. ; Athanasakis, K. ; Radova, L....
Value in Health.  26 (2023)  12 - p. S66 , 2023
Link: https://doi.org/10.1016/..
 
?
7

GENOMIC EVOLUTION AND RESISTANCE TO PIRTOBRUTINIB IN COVALE..:

Patel, K. ; Brown, J. R. ; Desikan, S. P....
Hematological Oncology.  41 (2023)  S2 - p. 185-187 , 2023
Link: https://doi.org/10.1002/..
 
?
8

GENOMIC EVOLUTION AND RESISTANCE TO PIRTOBRUTINIB IN COVALE..:

Brown, JR ; Woyach, JA ; Patel, K...
Hematology, Transfusion and Cell Therapy.  45 (2023)  - p. S160-S161 , 2023
Link: https://doi.org/10.1016/..
 
?
9

A MATCHING‐ADJUSTED INDIRECT COMPARISON OF THE EFFICACY AND..:

Ghia, P. ; Skarbnik, A. ; Miranda, M....
Hematological Oncology.  41 (2023)  S2 - p. 742-743 , 2023
Link: https://doi.org/10.1002/..
 
?
10

ZANUBRUTINIB (ZANU) VERSUS BENDAMUSTINE + RITUXIMAB (BR) IN..:

Shadman, M. ; Munir, T. ; Roback, T....
Hematological Oncology.  41 (2023)  S2 - p. 235-238 , 2023
Link: https://doi.org/10.1002/..
 
?
11

Ibrutinib (Ibr) for treatment of relapsed‐refractory (R/R) ..:

Ghia, P. ; Munir, T. ; Burger, J....
Hematological Oncology.  41 (2023)  S2 - p. 464-466 , 2023
Link: https://doi.org/10.1002/..
 
?
12

PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE..:

Barreto, RR ; Patel, K ; Coombs, C...
Hematology, Transfusion and Cell Therapy.  44 (2022)  - p. S139-S140 , 2022
Link: https://doi.org/10.1016/..
 
?
13

P597: HIGH DOSE IRON IMPAIRS MALIGNANT B-CELL VIABILITY IN ..:

Bordini, J. ; Lenzi, C. ; Toscani, L....
HemaSphere.  6 (2022)  - p. 496-497 , 2022
Link: https://doi.org/10.1097/..
 
?
14

P662: PATIENT-REPORTED OUTCOMES FROM A PHASE 3 RANDOMIZED S..:

Ghia, P. ; Barnes, G. ; Yang, K....
HemaSphere.  6 (2022)  - p. 560-561 , 2022
Link: https://doi.org/10.1097/..
 
?
15

P616: THE LOSS OF IΚBΕ INHIBITOR ACCELERATES DISEASE DEVELO..:

Lenzi, C. ; Bordini, J. ; Pseftogkas, A....
HemaSphere.  6 (2022)  - p. 515-516 , 2022
Link: https://doi.org/10.1097/..
 
1-15